InDex Moves Kappaproct into Phase III Ulcerative Colitis Trial
By Cormac Sheridan
Wednesday, March 7, 2012
InDex Pharmaceuticals AB is moving its lead drug candidate Kappaproct into a European Phase III trial in patients with chronic active ulcerative colitis who are unresponsive to other therapies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.